Tranexamic acid as maintenance treatment for non-histaminergic angioedema: Analysis of efficacy and safety in 37 patients

Clinical and Experimental Immunology

Volumn 178, Issue 1, 2014, Pages 112-117

  Wintenberger, C ^a   Boccon Gibod, I ^a,b   Launay, D ^c,d   Fain, O ^c,d,e   Kanny, G ^c,d,e,f   Jeandel, P Y ^c,d,e,f,g   Martin, L ^c,d,e,f,g,h   Gompel, A ^{c,d,e,f,g,h,i}   Bouillet, L ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b French Reference Center for Angioedema   (France)

^c UNIV LILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Angioedema; Bradykinin; Hereditary angioedema; Tranexamic acid

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; TRANEXAMIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; C1 INHIBITOR DEFICIENCY; CLINICAL ARTICLE; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; LEG PAIN; MAINTENANCE THERAPY; MALE; MIGRAINE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ANGIOEDEMAS, HEREDITARY; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ADULT; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANEXAMIC ACID;

EID: 84908216837     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12379     Document Type: Article

References (24)

1. Bouillet L, Ponard D, Drouet C, Massot C. [Non-histaminic angioedema management: diagnostic and therapeutic interest of tranexamic acid]. Rev Med Interne 2004; 25:924-6.
2. Zuraw BL. Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol 2008; 100:S13-8.
3. Bouillet L, Boccon-Gibod I, Massot C. Bradykinin mediated angioedema. Rev Med Interne 2011; 32:225-31.
4. Zuraw BL, Bork K, Binkley KE et al. [Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel]. Allergy Asthma Proc 2012; 33 (Suppl. 1):S145-56.
5. Bouillet L. [Hereditary angioedema: a therapeutic revolution]. Rev Med Interne 2012; 33:150-4.
6. Cicardi M, Bork K, Caballero T et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2011; 67:147-57.
7. Craig T, Aygoren-Pursun E, Bork K et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5:182-99.
8. Riedl M, Gower RG, Chrvala CA. Current medical management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy Asthma Immunol 2011; 106:316-22e4.
9. Blohme G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand 1972; 192:293-8.
10. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972; 286:808-12.
11. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287:452-4.
12. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol 1994; 93:870-6.
13. Dispenza MC, Craig TJ. Discrepancies between guidelines and international practice in treatment of hereditary angioedema. Allergy Asthma Proc 2012; 33:241-8.
14. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2010; 66:192-6.
15. Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic non histaminergic angioedema. Am J Med 1999; 106:650-4.
16. Costantino G, Casazza G, Bossi I, Duca P, Cicardi M. Long-term prophylaxis in hereditary angio-oedema: a systematic review. BMJ Open 2012; 2:e000524.
17. Temino VM, Peebles RS Jr. The spectrum and treatment of angioedema. Am J Med 2008; 121:282-6.
18. Bowen T, Brosz J, Brosz K, Hebert J, Ritchie B. Management of hereditary angioedema: 2010 Canadian approach. Allergy Asthma Clin Immunol 2010; 6:20-30.
19. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295:1444-8.
20. Tallroth GA. Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate. Int Arch Allergy Immunol 2011; 154:356-9.
21. Saule C, Boccon-Gibod I, Fain O et al. Benefits of progestin contraception in non allergic angioedema. Clin Exp Allergy 2013; 43:475-82.
22. Du-Thanh A, Raison-Peyron N, Drouet C, Guillot B. Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema. Allergy 2010; 65:793-5.
23. Chi C, Kulkarni A, Lee CA, Kadir RA. The obstetric experience of women with factor XI deficiency. Acta Obstet Gynecol Scand 2009; 88:1095-100.
24. Roberts I, Perel P, Prieto-Merino D et al. Effect of tranexamic acid on mortality inpatients with traumatic bleeding: pre specified analysis of data from randomised controlled trial. BMJ 2012; 345:e5839.